查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1959622

维生素K市场机会、成长要素、产业趋势分析及2026年至2035年预测

Vitamin K Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2025 年全球维生素 K 市场价值为 10.7 亿美元，预计到 2035 年将达到 24 亿美元，年复合成长率为 8.5%。

维生素K市场-IMG1

市场成长的驱动因素包括人们对维生素K在血液凝固、骨骼强度和心血管健康方面生理重要性的认识不断提高，以及老年人中心血管疾病和营养缺乏症发病率的上升。预防医学的发展趋势和对微量营养素补充剂日益增长的关注进一步强化了市场需求。维生素K因其在调节钙代谢和维持血管健康方面的作用，在临床营养和健康促进领域备受关注。随着消费者越来越重视长期健康益处，膳食补充剂的作用也从纠正营养缺乏转向积极主动的疾病风险管理。膳食补充剂应用范围的扩大、配方稳定性的提高以及补充剂和药品生物利用度的整体提升，也对市场产生了积极影响。生产方法和原材料采购的持续创新使製造商能够在满足不断增长的全球需求的同时，确保产品品质的稳定性。这些因素共同作用，在临床应用和主导健康意识的双重推动下，创造了一个稳定扩张的市场模式。

市场范围
开始年份 2025
预测年份 2026-2035
起始值 10.7亿美元
预测金额 24亿美元
复合年增长率 8.5%

维生素K是一种脂溶性营养素，对血液凝固、骨骼矿化以及激活维持心血管平衡的蛋白质至关重要。该市场包括主要用于治疗和营养补充剂的维生素K1，以及越来越多地用于维护骨骼和心臟健康的补充剂中的维生素K2。这两种形式的维生素K在调节钙转运和防止矿物质沉积异常方面发挥核心作用，并在从预防医学到治疗医学的广泛领域中都具有重要意义。

预计到2025年，维生素K1市占率将达到68.4%，并在2026年至2035年间以8.3%的复合年增长率成长。该细分市场持续保持主导地位，这主要得益于其在凝血相关疾病治疗和维生素K1缺乏症纠正方面的临床重要性。来自药品製剂和医用营养产品的强劲需求推动了其持续应用，而不断的产品优化也进一步提升了其在医疗保健领域的重要性。

预计到2025年，凝血酶原缺乏症市场规模将达2.758亿美元。这个市场之所以保持主导地位，是因为维生素K在合成和活化维持正常血液功能所需的凝血因子方面发挥着至关重要的作用。临床上对维生素K在凝血障碍治疗中的依赖性持续推动着市场需求的稳定成长，尤其是在医院治疗和急诊通讯协定。

预计到2025年，北美维生素K市占率将达到41.1%。先进的医疗保健体系、较高的预防保健意识以及营养补充剂的广泛应用，巩固了主导地位。持续增加研发投入、产品开发和高品质配方技术，推动了市场成长；同时，消费者对实证营养解决方案的偏好，也进一步增强了区域市场需求。

目录

第一章：调查方法和范围

第二章执行摘要

第三章业界考察

  • 生态系分析
  • 影响产业的因素
    • 促进因素
      • 人们对骨骼和心血管健康的认识不断提高
      • 营养补充品和维生素的广泛应用
      • 製剂技术和生物利用度的进步
      • 在製药领域不断拓展的应用
    • 产业潜在风险与挑战
      • 监管复杂性和合规要求
      • 过量服用和副作用的风险
    • 市场机会
      • 新兴市场健康意识日益增强
      • 个人化营养与数位健康的融合
  • 成长潜力分析
  • 监管环境
    • 北美洲
    • 欧洲
    • 亚太地区
  • 未来市场趋势
  • 波特的分析
  • PESTEL 分析

第四章 竞争情势

  • 介绍
  • 企业市占率分析
  • 公司矩阵分析
  • 主要市场公司的竞争分析
  • 竞争定位矩阵
  • 主要进展
    • 併购
    • 伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章 市场估计与预测：依类型划分，2022-2035年

  • 维生素K1
  • 维生素K2

第六章 市场估计与预测：依应用领域划分，2022-2035年

  • 骨质疏鬆症
  • 维生素K依赖性凝血因子缺乏症（VKCFD）
  • 凝血酶原缺乏症
  • 维生素K缺乏性出血（VKDB）
  • 皮肤涂抹
  • 其他用途

第七章 市场估计与预测：依给药途径划分，2022-2035年

  • 口服
    • 药片
    • 粉末
    • 液体
  • 肠外
  • 外用

第八章 市场估算与预测：依通路划分，2022-2035年

  • 离线
    • 大卖场/超级市场
    • 专卖店
    • 药局
  • 在线的

第九章 市场估计与预测：依地区划分，2022-2035年

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国

第十章：公司简介

  • Amphastar Pharmaceuticals
  • BASF SE
  • Country Life（Kikkoman）
  • DSM-Firmenich
  • Glanbia
  • Gnosis by Lesaffre
  • Kappa Bioscience
  • Livealth Biopharma
  • Lonza
  • Nature's Bounty（Nestle Health Science）
  • Nature Made（Pharmavite）
  • NOW Foods
  • Pfizer
  • Solgar
简介目录
Product Code: 1481

The Global Vitamin K Market was valued at USD 1.07 billion in 2025 and is estimated to grow at a CAGR of 8.5% to reach USD 2.4 billion by 2035.

Vitamin K Market - IMG1

Market growth is supported by rising awareness of the physiological importance of vitamin K in blood coagulation, bone strength, and cardiovascular wellness, alongside a growing incidence of cardiovascular conditions and nutrient deficiencies among older populations. Preventive healthcare trends and increased focus on micronutrient supplementation are further strengthening demand. Vitamin K has gained significant attention in clinical nutrition and wellness applications due to its role in regulating calcium metabolism and maintaining vascular integrity. As consumers increasingly prioritize long-term health outcomes, supplementation has moved beyond deficiency correction to proactive disease risk management. The market is also benefiting from expanding nutraceutical usage, improved formulation stability, and enhanced bioavailability across supplement and pharmaceutical products. Continuous innovation in production methods and ingredient sourcing is allowing manufacturers to deliver consistent quality while addressing rising global demand. Together, these factors are shaping a steadily expanding market landscape supported by both clinical utilization and consumer-driven wellness adoption.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$1.07 Billion
Forecast Value$2.4 Billion
CAGR8.5%

Vitamin K represents a class of fat-soluble nutrients that are essential for activating proteins responsible for coagulation, bone mineralization, and cardiovascular balance. The market includes vitamin K1, primarily used in therapeutic and dietary formulations, and vitamin K2, which is increasingly incorporated into supplements designed to support skeletal and heart health. Both forms play a central role in regulating calcium transport and preventing improper mineral deposition, making them critical across preventive and therapeutic healthcare applications.

The vitamin K1 segment accounted for 68.4% share in 2025 and is expected to grow at a CAGR of 8.3% during 2026-2035. This segment continues to lead due to its established clinical importance in managing coagulation-related conditions and correcting deficiency states. Strong demand from pharmaceutical formulations and medical nutrition products supports its sustained adoption, while ongoing product optimization is reinforcing its relevance across healthcare settings.

The prothrombin deficiency segment generated USD 275.8 million in 2025. This segment maintained a leading position as vitamin K remains essential for the synthesis and activation of clotting factors required for normal blood function. Clinical reliance on vitamin K for managing coagulation disorders continues to drive consistent demand, particularly within hospital-based and acute care treatment protocols.

North America Vitamin K Market held 41.1% share in 2025. Regional leadership is supported by advanced healthcare systems, strong preventive health awareness, and widespread adoption of dietary supplementation. Continued investment in research, product development, and high-quality formulation technologies is reinforcing market growth, while consumer preference for scientifically backed nutritional solutions further strengthens regional demand.

Key companies operating in the Global Vitamin K Market include Pfizer, BASF SE, DSM-Firmenich, Lonza, Glanbia, Amphastar Pharmaceuticals, Gnosis by Lesaffre, Kappa Bioscience, Country Life (Kikkoman), Nature Made (Pharmavite), Nature's Bounty (Nestle Health Science), NOW Foods, Solgar, and Livealth Biopharma, with competitive positioning driven by diversified portfolios and global distribution capabilities. Companies active in the vitamin K market are strengthening their market position through continuous investment in formulation innovation, bioavailability enhancement, and product differentiation. Manufacturers are focusing on developing high-purity and stable vitamin K ingredients that meet pharmaceutical and nutraceutical quality standards. Strategic partnerships with healthcare providers and nutrition brands are expanding market reach, while geographic expansion into emerging regions is supporting long-term growth.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research approach
  • 1.3 Quality commitments
    • 1.3.1 GMI AI policy and data integrity commitment
      • 1.3.1.1 Source consistency protocol
  • 1.4 Research trail and confidence scoring
    • 1.4.1 Research trail components
    • 1.4.2 Scoring components
  • 1.5 Data collection
    • 1.5.1 Partial list of primary sources
  • 1.6 Data mining sources
    • 1.6.1 Paid sources
      • 1.6.1.1 Sources, by region
  • 1.7 Base estimates and calculations
    • 1.7.1 Revenue share analysis
    • 1.7.2 Base year calculation
  • 1.8 Forecast model
  • 1.9 Research transparency addendum
    • 1.9.1 Source attribution framework
    • 1.9.2 Quality assurance metrics
    • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Type trends
    • 2.2.3 Application trends
    • 2.2.4 Route of administration trends
    • 2.2.5 Distribution channel trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing awareness of bone and cardiovascular health
      • 3.2.1.2 Growing adoption of nutraceuticals and dietary supplements
      • 3.2.1.3 Advancements in formulation and bioavailability
      • 3.2.1.4 Expanding pharmaceutical applications
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Regulatory complexity and compliance requirements
      • 3.2.2.2 Risk of overdosing and side effects
    • 3.2.3 Market opportunities
      • 3.2.3.1 Emerging markets with rising health awareness
      • 3.2.3.2 Integration with personalized nutrition and digital health
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Future market trends
  • 3.6 Porter’s analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Vitamin K1
  • 5.3 Vitamin K2

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Osteoporosis
  • 6.3 Vitamin K-dependent clotting factors deficiency (VKCFD)
  • 6.4 Prothrombin deficiency
  • 6.5 Vitamin K deficiency bleeding (VKDB)
  • 6.6 Dermal applications
  • 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
    • 7.2.1 Pills
    • 7.2.2 Powders
    • 7.2.3 Liquids
  • 7.3 Parenteral
  • 7.4 Topical

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 Offline
    • 8.2.1 Hypermarkets/ supermarkets
    • 8.2.2 Specialty stores
    • 8.2.3 Pharmacy stores
  • 8.3 Online

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 India
    • 9.4.3 Japan
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Amphastar Pharmaceuticals
  • 10.2 BASF SE
  • 10.3 Country Life (Kikkoman)
  • 10.4 DSM-Firmenich
  • 10.5 Glanbia
  • 10.6 Gnosis by Lesaffre
  • 10.7 Kappa Bioscience
  • 10.8 Livealth Biopharma
  • 10.9 Lonza
  • 10.10 Nature's Bounty (Nestle Health Science)
  • 10.11 Nature Made (Pharmavite)
  • 10.12 NOW Foods
  • 10.13 Pfizer
  • 10.14 Solgar